MapLight Therapeutics, Inc. (MPLT)
NASDAQ: MPLT · Real-Time Price · USD
13.77
+0.63 (4.79%)
Sep 4, 2026, 4:00 PM EDT - Market closed
MapLight Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, MapLight Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $26.54. The average 1-year stock price forecast is 92.74% higher than the current stock price, while the lowest is $13 (-5.59%) and the highest is $43 (+212.27%).
Price Target: $26.54 (+92.74%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for MapLight Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 9 | 10 | 12 | 11 |
| Buy | 1 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 7 | 11 | 12 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Buy Reiterates $45 → $43 | Buy | Reiterates | $45 → $43 | +212.27% | Aug 31, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Reiterates $21 | Hold | Reiterates | $21 | +52.51% | Aug 17, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $37 | Buy | Maintains | $37 | +168.70% | Aug 14, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $46 → $20 | Buy | Maintains | $46 → $20 | +45.24% | Aug 14, 2026 |
| UBS | UBS | Hold Downgrades $52 → $13 | Hold | Downgrades | $52 → $13 | -5.59% | Aug 10, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
16.67M
EPS This Year
-4.64
from -18.56
EPS Next Year
-3.30
from -4.64
EPS and Forward PE are based on non-GAAP adjusted numbers.